New pill targets Hard-to-Treat cancers with RAS gene flaw

NCT ID NCT07252479

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an experimental pill, AN9025, in adults with advanced solid tumors that have a specific genetic change called a RAS mutation. The main goal is to find a safe dose and check for side effects. About 118 participants will take the drug daily or weekly and be closely monitored for several months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • H. Lee Moffit Cancer Center and Research Institute Hospital, Inc.

    NOT_YET_RECRUITING

    Tampa, Florida, 33612-9497, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    RECRUITING

    Orlando, Florida, 32827, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••